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Abstract
Background: Most conventional methods for delivering chemotherapeutic agents fail to achieve therapeutic
concentrations of drugs, despite reaching toxic systemic levels. Novel controlled drug delivery systems are
designed to deliver drugs at predetermined rates for predefined periods at the target organ and overcome the
shortcomings of conventional drug formulations therefore could diminish the side effects and improve the life
quality of the patients. Thus, a suitable controlled drug delivery system is extremely important for chemotherapy.
Results: A novel biodegradable thermosensitive composite hydrogel, based on poly(ethylene glycol)-poly(ε-
caprolactone)-poly(ethylene glycol) (PEG-PCL-PEG, PECE) and Pluronic F127 copolymer, was successfully
prepared in this work, which underwent thermosensitive sol-gel-sol transition. And it was flowing sol at ambient
temperature but became non-flowing gel at body temperature. By varying the composition, sol-gel-sol transition
and in vitro drug release behavior of the composite hydrogel could be adjusted. Cytotoxicity of the composite
hydrogel was conducted by cell viability assay using human HEK293 cells. The 293 cell viability of composite
hydrogel copolymers were yet higher than 71.4%, even when the input copolymers were 500 μg per well. Vitamin
B12 (VB12), honokiol (HK), and bovine serum albumin (BSA) were used as model drugs to investigate the in vitro
release behavior of hydrophilic small molecular drug, hydrophobic small molecular drug, and protein drug from
the composite hydrogel respectively. All the above-mentioned drugs in this work could be released slowly from
composite hydrogel in an extended period. Chemical composition of composite hydrogel, initial drug loading, and
hydrogel concentration substantially affected the drug release behavior. The higher Pluronic F127 content, lower
initial drug loading amount, or lower hydrogel concentration resulted in higher cumulative release rate.
Conclusion: The results showed that composite hydrogel prepared in this paper were biocompatible with low
cell cytotoxicity, and the drugs in this work could be released slowly from composite hydrogel in an extended
period, which suggested that the composite hydrogel might have great potential applications in biomedical fields.
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Cancer is a major public health problem in the world,
which causes millions of death each year. Approximately
1.5 million new cancer cases and more than 500,000
deaths from cancer are projected to occur in 2008 in USA
[1]. Now, one in four deaths in USA is due to cancer. As
conventional therapy for cancer, chemotherapy has wide
applications in clinical, which has been proven to be
effective. Although chemotherapeutic agents may prolong
the survival time of the patients, unfortunately most of
them have severe side toxic effects, which would decline
the life quality of patients. Most conventional methods
for delivering chemotherapeutic agents, such as intrave-
nous injection or oral ingestion, fail to achieve therapeutic
concentrations of drugs, despite reaching toxic systemic
levels. Novel controlled drug delivery systems (DDS) are
designed to deliver drugs at predetermined rates for prede-
fined periods at the target organ, which could be used to
overcome the shortcomings of conventional drug formu-
lations, therefore could diminish the side effects and
improve the life quality of the patients [2,3]. Thus, a suit-
able controlled drug delivery system is extremely impor-
tant for chemotherapy.
Hydrogels are a special class of macromolecules, which
could absorb much water while maintaining their integ-
rity in water. Over the past decades, the stimuli-sensitive
hydrogel has attracted increasing attention owing to their
responsiveness to the environmental stimulus, including
chemical substances and changes in temperature, pH, or
electric field [4-9]. The biodegradable thermosensitive
physical crosslinked hydrogels have been extensively
studied due to their great biodegradability, biocompati-
bility, and responsiveness to temperature. Therefore, bio-
degradable thermosensitive hydrogels have been
investigated as in situ gel-forming system, such as control-
led drug delivery, tissue repair, and cell encapsulation [10-
20].
Poly(ethylene glycol)-poly(propylene glycol)-poly(ethyl-
ene glycol) triblock copolymer (PEG-PPG-PEG), known
as Pluronic or Poloxamer, has been extensively studied as
a potential drug delivery vehicle due to their excellent bio-
compatibility and thermosensitivity [21,22]. These copol-
ymers have been widely used as emulsifiers, wetting
agents, and solubilizers [23]. However, due to weak
hydrophobicity of PPG block, the Pluronic F127 copoly-
mer forms a fast-eroding gel and could persist a few hours
in vivo at most, which greatly restricted its application as
in situ gel-forming controlled drug delivery system.
In our previous study, we prepared a new kind of biode-
gradable and injectable thermosensitive poly(ethylene
glycol)-poly(ε-caprolactone)-poly(ethylene glycol) (PEG-
PCL-PEG, PECE) hydrogel controlled drug delivery sys-
tem [24]. At low temperature, PECE hydrogel is injectable
flowing sol, which could be easily mixed with pharmaceu-
tical agent, and it forms non-flowing gel at body tempera-
ture as sustained drug delivery site in vivo. PCL and PEG
are biocompatible and have been widely used in several
FDA approved products [25-30]. PCL is lack of toxicity
and has great permeability [31]. Due to combination of
great advantages of PEG and PCL, the PECE hydrogel
might have great potential application in biomedical
field.
In our last work [32], we prepared a new biodegradable
and injectable composite hydrogel based on PECE and
Pluronic F127 copolymer. The composite hydrogel under-
goes sol-gel-sol transition, which is free flowing sol at
room temperature and becomes a non-flowing gel at body
temperature. Our last work mainly focused on the synthe-
sis, in vivo gel formation and degradation assay, and toxic-
ity evaluation of the composite hydrogel. It is well known
that Pluronic copolymer forms a fast-eroding hydrogel
which could not persist longer than a few hours. And
PECE hydrogel could persist 2 weeks in vivo [24]. Accord-
ing to our results, by simply altering the composition of
PECE and Pluronic F127 copolymers, the in vivo sustained
time of the composite hydrogel could be controlled,
which could meet the different requirements of in vivo sus-
tained time, therefore the composite hydrogel is very use-
ful for its potential application as injectable in situ gel-
forming drug delivery system.
In the present study, cytotoxicity and in vitro drug release
behavior of the composite hydrogel were studied in detail.
Many factors affecting in vitro drug release behavior of the
composite hydrogel were investigated, including different
kinds of drugs, initial drug loading, concentration of com-
posite hydrogel, and chemical composition of the com-
posite hydrogel. By altering the composition of composite
hydrogel, sol-gel-sol transition behavior and in vitro drug
release behavior of the prepared composite hydrogel
could be controlled, which was of great importance for




Poly(ethylene glycol) methyl ether (MPEG, Mn = 550,
Aldrich, USA), ε-Caprolactone (ε-CL, Alfa Aesar, USA),
Pluronic F127 (Fluka, USA), Hexamethylene diisocyanate
(HMDI, Aldrich, USA), Stannous octoate (Sn(Oct)2,
Sigma, USA), Dulbecco's modified Eagle's medium
(DMEM, Sigma, USA), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT, Sigma, USA),
bovine serum albumin (BSA, BR, BoAo Co. Ltd, China)
and VB12 (Sigma, USA) were used without further purifi-
cation. Honokiol (HK) were isolated and purified in ourPage 2 of 13
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reagent (AR) grade and used as received.
Preparation of composite hydrogel
PECE copolymer were synthesized and purified as
reported previously [24]. Briefly, PEG-PCL diblock copol-
ymers were prepared by ring opening polymerization of ε-
CL initiated by MPEG using stannous octoate as catalyst;
PEG-PCL-PEG triblock copolymers were synthesized by
coupling PEG-PCL diblock copolymers using HMDI as
coupling agent [18,24]. The just-obtained PECE block
copolymers were dissolved in dichloromethane, and then
reprecipitated from the filtrate using excess cold petro-
leum ether. Then, the mixture was filtered and vacuum
dried to constant weight at room temperature. The puri-
fied copolymers were kept in air-tight bags before further
use.
The obtained PECE copolymer was characterized by FTIR
(NICOLET 200SXV, Nicolet, USA), 1H-NMR (Varian 400
spectrometer, Varian, USA), and GPC (Agilent 110 HPLC,
USA). The Mn and PEG/PCL ratio of PECE triblock copol-
ymer calculated from 1H-NMR spectra was 3408 and 960/
2448 respectively. Macromolecular weight and macromo-
lecular weight distribution (polydispersity, PDI, Mw/Mn)
of PECE triblock copolymer determined by GPC were
4391 and 1.30 respectively [24].
Preparation scheme of composite hydrogel was described
in Fig. 1. Aqueous PECE solutions were prepared by dis-
solving PECE copolymers in deionized water at a desig-
nated temperature then cooled to 4°C. Then, different
amounts of Pluronic F127 were dissolved in icy cold
deionized water to a transparent solution. Subsequently,
the obtained two solutions were mixed together under
mild agitation to obtain a homogeneous liquid solution.
The final solution contained a given concentration and
composition of the two copolymers to form the different
composite hydrogel samples. The composite hydrogels
prepared in this work were listed in Table 1.
Sol-gel-sol phase transition behavior study
Sol-gel-sol phase transition diagrams of composite hydro-
gels were recorded using test tube-inverting method
[18,24]. The sol-gel-sol transition was visually observed
by inverting the vials, and conditions of sol and gel were
defined as "flowing" and "non-flowing" in one minute,
respectively.
In this work, the volume of the composite hydrogel solu-
tion was kept to 0.5 mL in total, regardless of the concen-
tration. After incubated in water bath at 4°C for 20
minutes, the hydrogel samples were slowly heated at a
rate of 0.5°C/min, from 4°C to the temperature when the
sol states occurred again.
Cytotoxicity assay of composite hydrogel
Cytotoxicity evaluation of composite hydrogel (S1, S3, S4,
and S6) was performed by 3- [4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide (MTT) assay using
HEK293 cells, which were grown in DMEM with 10% of
fetal bovine serum (FBS) and were cultured in a humidi-
fied atmosphere containing 5% CO2 at 37°C. Cell suspen-
sions were distributed in a 96-well plate at a density of 1
× 104 cells/well in DMEM medium with 10% of FBS for 24
hours. Then, the medium were replaced by 200 μl of fresh
DMEM per well containing different amounts of compos-
ite hydrogel copolymers (the amount of PECE and
Pluronic F127 copolymer, which do not contain water)
from 50 μg/ml to 2500 μg/ml, respectively. After 48
hours, the cell cultures were washed with PBS solution
and MTT assay was conducted. Untreated cells were taken
as control with 100% viability. The cell cytotoxicity of
composite hydrogel was defined as the relative viability
(%) which correlates with amount of liable cells com-
pared with cell control.
Preparation of honokiol micelles
Honokiol (HK) micelles were prepared and characterized
in our previous work [34]. Briefly, certain amount of HK
was dissolved into Et Ac to form HK solution. Then, the
prepared HK-Et Ac solution was introduced into 4 ml of
F127 aqueous solution at the concentration of 5%w/w
under extreme stirring by T10 (T10, IKA, German). About
10 min later, oil in water (O/W) emulsion well formed.
Then, Et Ac was evaporated in rotator evaporator
((BÜCHI, Switzerland) and the HK micelles were
obtained. The content of HK in the prepared HK micelles
suspension was determined by high-performance liquid
chromatography (HPLC). At last, the HK micelles slurry
Table 1: The composite hydrogels prepared in this work
Code PECE : Pluronic F127 (w/w, %) Phase transition The concentration region with phase transition behavior (Wt%)
S1 100 : 0 Sol-gel-sol 15% to 35%
S2 80 : 20 Sol-gel-sol 25% to 35%
S3 60 : 40 Sol-gel-sol 20% to 35%
S4 40 : 60 Sol-gel-sol 20% to 35%
S5 20 : 80 Sol-gel-sol 20% to 35%
S6 0 : 100 Sol-gel-sol 15% to 35%Page 3 of 13
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Preparation scheme of demonstrated injectable thermosensitive composite hydrogelFigure 1
Preparation scheme of demonstrated injectable thermosensitive composite hydrogel. PECE hydrogel solutions 
were prepared by dissolving PECE copolymers in deionized water at a designated temperature then cooled to 4°C. Then, 
pluronic F127 were dissolved in icy cold deionized water to a transparent solution. Subsequently, the obtained two solutions 
were mixed together under mild agitation to obtain homogeneous liquid solution, and then drug were added into the compos-
ite hydrogel. The prepared hydrogel containing drug was inhaled into injector and injected into or around the focus of infection 
in animal. Thus, composite sol turned into gel state and acted as depots for sustained release of drug in situ when the cold sol 
is warmed to body temperature (37°C)in vivo. At last, for the degradation of the composite hydrogel, the introduced drug 
delivery system was gradually emanated from body.
BMC Biotechnology 2009, 9:8 http://www.biomedcentral.com/1472-6750/9/8was lyophilized and the power was stored at 4°C before
further use.
In vitro drug release behavior from the composite 
hydrogel
Release behavior of hydrophilic small molecular drugs
VB12 was used as model to determine the release behavior
of hydrophilic small molecular drug from composite
hydrogel in vitro. 200 μl of VB12 loaded composite hydro-
gel (30 wt% of S1 with 1 mg of VB12, 30 wt% of S4 with 1
mg of VB12, 30 wt% of S6 with 1 mg of VB12, 30 wt% of S3
with 1 mg of VB12, 30 wt% of S3 with 2 mg of VB12, 20
wt% of S3 with 1 mg of VB12, respectively) were placed
into 4 mL-Eppendorf (EP) tubes and allowed to gel in an
incubator at 37°C for 12 h. Then, the gels were immersed
in 1 mL of PBS (pH = 7.4) and were shaken at 100 rpm at
37°C. At specific time intervals, all the release media were
removed and replaced by fresh release media. After centri-
fuged at 13000 rpm for 10 min, the supernatant of the
removed release media were collected and stored at -20°C
until analysis. The collected supernatants were detected
on UV spectrophotometer at 362 nm to determine the
concentration of VB12. The accumulatively released VB12
was calculated according to the following equation [24]:
Q = CnVt + VsΣCn-1 (1)
Where Q was accumulatively released weight, and Cn was
the VB12 concentration at time t. Vt was the volume of
medium (Vt = 1 mL), and Vs was the volume of solution
removed from supernatant (Vs = 1 mL).
Release behavior of hydrophobic small molecular drugs
Freshly prepared HK micelles loaded composite hydrogel
were used to assay in vitro release behavior of hydrophobic
small molecular drugs. In detail, 200 μl of prepared HK
micelles loaded composite hydrogel (30 wt% of S1 with 1
mg of HK, 30 wt% of S3 with 1 mg of HK, 30 wt% of S6
with 1 mg of HK, 30 wt% of S4 with 1 mg of HK, 30 wt%
of S4 with 2 mg of HK, 20 wt% of S4 with 1 mg of HK,
respectively) were transferred into 4 mL-EP tubes and
allowed to gel in an incubator at 37°C for 12 h. Then, the
gels were immersed in 1 mL of PBS (pH = 7.4) and were
shaken at 100 rpm at 37°C. At specific time intervals, all
the release media were removed and replaced by fresh
release media. After centrifuged at 13000 rpm for 10 min,
the supernatant of the removed release media were col-
lected and stored at -20°C until analysis.
The concentration of HK was determined by HPLC Instru-
ment (Waters Alliance 2695). Solvent delivery system
equipped with a column heater and a plus autosampler.
Detection was taken on a Waters 2996 detector. Chroma-
tographic separations were performed on a reversed phase
C18 column (4.6 × 150 mm–5 um, Sunfire Analysis col-
umn). And the column temperature was kept at 28°C.
Acetonitrile/water (60/40, v/v) was used as eluent at a
flow rate of 1 mL/min. The standard curve equation is: H
= 105000*X+4680 (H: The area of peak; X: the concentra-
tion of HK) and the correlation coefficient is 0.999994.
Release behavior of hydrophilic macromolecular protein drugs
In vitro release behavior of BSA, which was used as the
model protein or peptide drug, from BSA loaded compos-
ite hydrogel was studied in detail. The procedure was sim-
ilar to section 2.7.2, except that the initial drug loading
amount were 4 mg and 8 mg, respectively. The amount of
BSA present in the supernatant was determined by bicin-
choninic acid (BCA) assay using BCA™ Protein Assay Kit
(PIERCE, USA). The SDS-polyacrylamide gel electro-
phoretic (SDS-PAGE) analysis was used to assay the stabil-
ity of BSA in the supernatant.
All the release study experiments were repeated three
times. All data are expressed as the mean ± S.D.
Scanning electron microscopy (SEM) of composite 
hydrogel
SEM was employed to investigate morphology of compos-
ite hydrogel before and after drug release. The composite
hydrogels (before drug release test and 8 hours after drug
released) were quickly frozen in liquid nitrogen and
lyophilized at -45°C for 72 h. The composite hydrogels
were sputtered with gold before observation. In this study,
morphology of prepared composite hydrogels was exam-
ined on JEOL SEM (JSM-5900LV, JEOL, Japan).
Results and discussion
Synthesis of PECE copolymers
The synthesis of PECE triblock copolymers has been
reported in our previous work [18,24]. Briefly, ring-open-
ing copolymerization of ε-CL onto MPEG was performed
to synthesis PEG-PCL diblock copolymers, and stannous
octoate was used as catalyst. PEG-PCL diblock copolymers
were then coupled using HMDI as coupling agent to pro-
duce the biodegradable PEG-PCL-PEG triblock copoly-
mers.
Temperature-dependent sol-gel-sol transition behavior
PECE and Pluronic F127 copolymers are both
amphiphilic in nature, whose aqueous solution individu-
ally presented sol-gel-sol transition behavior. The com-
posite hydrogel prepared in this work were composed of
the two copolymers. As presented in Table 1, composite
hydrogel based on PECE and Pluronic F127 copolymers
from S1 to S6 all showed temperature-dependent reversi-
ble sol-gel-sol phase transition. The composite hydrogel
flowed freely at lower temperature, but became a non-
flowing gel at body temperature about 37°C (Fig. 2). Fig.
3 presented the sol-gel-sol phase transition diagrams ofPage 5 of 13
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centrations are above the critical gelation concentration
(CGC), aqueous solutions of composite hydrogel
changed from "sol" phase to "gel" phase with increase in
temperature to the lower critical gelation temperature
(LCGT). With further increase of temperature to upper
critical gelation temperature (UCGT), the sol phase
occurs.
According to Fig. 3, pure PECE hydrogel (S1) and pure
Pluronic F127 hydrgel (S6) both have a CGC of approxi-
mately 15 wt%, but S6 have a much wider gelation win-
dow than that of S1. The UCGT of S6 at the concentration
of 30 wt% and 35% was not detected from 0°C to 100°C.
The CGC of S2, S3, S4, and S5 were 25 wt%, 20 wt%, 20
wt%, and 20 wt%, respectively, which were much higher
than that of two pure hydrogels. By mixing the two hydro-
gel together, the CGC of the composite hydrogel increased
accordingly. CGC of S2 increased approximately 10 wt%
than that of S1, whereas CGC of S5 increased approxi-
mately 5 wt% than that of S6. This phenomenon indi-
cated that concerning CGC, the influence of Pluronic
F127 hydrogel on PECE hydrogel was more dramatic than
that of PECE hydrogel on Pluronic F127 hydrogel. As
shown in Fig. 3, with increase in PECE hydrogel content
in composite hydrogel, the UCGT decreased significantly,
whereas the LCGT increased slightly. The UCGT of S6
hydrogel at concentration of 30 wt% and 35 wt% could
Photograph of composite hydrogel (30 wt%) at different temperatureFigure 2
Photograph of composite hydrogel (30 wt%) at different temperature. S6 at 10°C (A) and 37°C (B); S4 at 10°C (C) 
and 37°C (D); S3 at 10°C (E) and 37°C (F); S1 at 10°C (G) and 37°C (H).
Sol-gel-sol transition phase diagram of composite hydrogelFigure 3
Sol-gel-sol transition phase diagram of composite hydrogel.Page 6 of 13
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centration of 30 wt% and 35 wt% were detected in S5 and
S3 hydrogel, respectively, due to increase in PECE content.
Therefore, it was obvious that sol-gel-sol transition behav-
ior of composite hydrogel depended on the composition
of the PECE and Pluronic F127 hydrogel. In fact, by alter-
ing the composition of composite hydrogel, the tempera-
ture range of sol-gel-sol phase transition could be
broadened to a certain extent, which might be very useful
for their further application as injectable in situ gel-form-
ing drug delivery system.
Cytotoxicity study of composite hydrogel copolymers
The cytotoxicity of the prepared composite hydrogels (S1,
S3, S4, and S6) was evaluated by cell viability assay using
HEK 293 cells. Fig. 4 exhibited the HEK 293 cell viability
of composite hydrogel copolymer with different concen-
tration gradient. As shown in Fig. 4, with increase of com-
posite hydrogel copolymer amount, HEK 293 cell viability
decreased accordingly. However, the 293 cell viability of
S1, S3, S4 and S6 copolymers were yet higher than 72.5%,
76.6%, 78.0% and 71.4%, respectively, even when the
input copolymers were 500 μg per well. According to Fig.
4, the HEK 293 cell viability of composite hydrogel copol-
ymer decreased as increase of composite hydrogel copoly-
mers. Compared with S3 and S4 copolymers group, S1
copolymer has higher cell viability at 20 μg/well or lower,
but cell viability decreased significantly at 50 μg/well or
higher. Cell viability study implied that the composite
hydrogel copolymers prepared in this paper were biocom-
patible with low cell cytotoxicity. Therefore, composite
HEK 293 cell viability assayFigure 4
HEK 293 cell viability assay. Cell containing 1 × 104 cells in DMEM containing 10% FBS was incubated with S1, S3, S4 and S6 
copolymers in 96-well in a humidified atmosphere containing 5% CO2 at 37°C for 48 h. Error bars represent the standard devi-
ation (n = 6).Page 7 of 13
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and is very promising for in situ gel-forming controlled
drug delivery system.
In vitro drug release profile of composite hydrogel
VB12, HK, and BSA were used as model drugs to investi-
gate the release behavior of hydrophilic small molecular
drug, hydrophobic small molecular drug, and protein
drug from drug loaded composite hydrogels, respectively.
Effect of the hydrogel composition, initial drug loading,
and concentration of composite hydrogel on in vitro drug
release behavior of the composite hydrogel were investi-
gated in detail, which were discussed as follows.
Release behavior of hydrophilic small molecular drug
In vitro release profile of VB12 from composite hydrogel in
PBS was studied, and the results were shown in Fig. 5.
According to Fig. 5, VB12 could be released in a sustained
period. The hydrogel composition had great effect on VB12
release profile, and the results were shown in Fig. 5–A. S6
hydrogel disappeared completely in 12 hours with a
cumulative release rate of approximately 94.2%, whereas
S1 and S4 hydrogel could maintain their integrity in the
whole release period. VB12 released faster and reached
higher cumulative release rate (90.0%) from S3 hydrogel
compared to S1 hydrogel (82.9%), which should be con-
In vitro release behavior of VB12 from composite hydrogelFigure 5
In vitro release behavior of VB12 from composite hydrogel. A: release behavior of S1, S4, an S6 hydrogel with the same 
hydrogel concentration (30 wt%) and initial drug loading amount (1 mg). B: release behavior of 30 wt% S3 hydrogel with differ-
ent initial drug loading amount (1 mg and 2 mg). C: release behavior of 1 mg VB12 loaded S3 hydrogel with different hydrogel 
concentration (20 wt% and 30 wt%). Error bars represent the standard deviation (n = 3).Page 8 of 13
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Pluronic F127 in S3 hydrogel.
Effect of initial drug loading amount on release profile of
S3 hydrogel was investigated. As shown in Fig. 5–B, S3
hydrogel containing twice amount of VB12 result in a sig-
nificant decrease of cumulative release rate from 86.3% to
72.4%, which was constant to our previous work. With
the same initial drug loading amount but lower hydrogel
concentration (20 wt%) of S3, VB12 released faster and
reached higher cumulative release rate (96.7%) compared
to 30 wt% concentration S3 hydrogel (86.3%). Due to the
higher composition of fast-eroding Pluronic F127 copoly-
mer and lower hydrogel concentration, the 20 wt% S3
hydrogel was completely eroded in 48 hours. In 20 wt%
hydrogel, an initial burst release of 25.6% of loaded VB12
occurred in the first one hour, followed by release of
94.7% in two days, whereas, in 30 wt% hydrogel, the
cumulative release rate of one hour, two days and 7 days
were 22.3%, 82.5%, and 86.3%, respectively.
Release behavior of hydrophobic small molecular drug
HK, as multi-functional drug, have great potential appli-
cation in human disease therapy, especially in cancer ther-
apy. Previously, a rapid separation approach to isolate
and purify HK had been developed using high-capacity
high-speed counter-current chromatography (high-capac-
ity HSCCC) by Chen et al in our lab [33]. For its great
potential application and high hydrophobicity, HK was
chosen for the hydrophobic model drug in this in vitro
drug release study.
Due to high hydrophobicity, HK could not be well-dis-
perse in the composite hydrogel to form homogeneous
solution. HK micelles were employed to solve above-men-
tioned problem. The obtained HK micelles with average
particle size of 33.34 nm and polydisperse index (PDI) of
0.036 could be well-dispersed in water, and it was stable.
Only Pluronic F127, a composition of composite hydro-
gel, was remained in the HK micelles, which would not
affect in vitro release behavior of composite hydrogel.
The release behavior of HK from composite hydrogel was
performed and the cumulative release profile was pre-
sented in Fig. 6. In Fig. 6–A, with increase in content of
Pluronic F127 copolymer from 0% (S1) to 100% (S6),
cumulative release rate and burst release rate (in one
hour) increased from 37.1% to 86.5% and from 1.4% to
8.9%, respectively. According to Fig. 6–B, with increase of
initial drug loading amount, the cumulative release rate of
HK decreased dramatically from 62.1% to 51.0% in a 14-
day period. As shown in Fig. 6–C, lower concentration of
composite hydrogel led to higher cumulative release rate
in a shorter time. Compared with VB12release profile,
cumulative release rate and burst release rate of HK were
much lower, which should be contributed to the high
hydrophobicity of HK.
Release behavior of hydrophilic macromolecular protein 
drugs
In vitro release behavior of protein or peptide model drug
from composite hydrogel was investigated, and the data
were summarized in Fig. 7–A, B, and 7C. BSA could be
released slowly from composite hydrogel in an extended
period. As presented in Fig. 7–A, B, and 7C, effects of
hydrogel composition, initial drug loading amount, and
hydrogel concentration on BSA release profile were inves-
tigated in detail. The results were similar to the influence
of these factors on HK release profile. SDS-PAGE was per-
formed to evaluate the stability of BSA in the in vitro
release period. According to Fig. 7–D, the major band for
BSA appeared at about 67 KD (lane2 to lane10) according
to the protein marker, which showed that BSA was stable
in the experimental period.
Thus, composition of composite hydrogel, initial drug
loading amount, and hydrogel concentration substan-
tially affected the drug release behavior of composite
hydrogel, where higher Pluronic F127 content, lower ini-
tial drug loading amount, or lower hydrogel concentra-
tion resulted in higher cumulative release rate, which
means drug release rate of composite hydrogel could be
controlled by simply altering the composition of PECE
and Pluronic F127 copolymers. It is obvious that the
influence of above-mentioned three factors is more dra-
matic on HK and BSA than VB12. Due to the great water
solubility, VB12 was released very fast from the composite
hydrogel, which could weaken the influence of the factors.
Besides the factors mentioned above, physical and chem-
ical property of the drugs played an important role in their
release behavior. According to Fig. 5 to Fig. 7, compared
with hydrophobic small molecular drug, hydrophilic
small molecular drug reached a higher cumulative release
rate in a shorter period. In addition, cumulative release
rate of hydrophilic small molecular drug was much higher
than that of hydrophilic large molecular drugs.
Morphology of composite hydrogel
Interior morphology of composite hydrogel before and 8
hours after drug released was investigated by SEM. The
composite hydrogels were frozen in liquid nitrogen and
lyophilized for 72 h before the test. According to Fig. 8, all
the hydrogel samples showed porous three-dimension
structure, but the shape and mesh size of pores in the
hydrogel were different. As shown in Fig. 8–A, S1 hydrogel
before drug release presented approximately spherical
pore with small mesh size. S3 hydrogel (Fig. 8–C), com-
posed of 60% PECE hydrogel and 40% Pluronic F127
hydrogel, also showed spherical pores, but have largerPage 9 of 13
(page number not for citation purposes)
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S1 and S3 hydrogel suggested that the composition of
composite hydrogel have great influence on their interior
structure, which dramatically affected the drug release
behavior of composite hydrogel. Eight hours after drug
released, S1 hydrogel could maintain its integrity, but the
hydrogel surface eroded (Fig. 8–B). In Fig. 8–D, S3 hydro-
gel after immersed in PBS for 8 hours showed large pores
and cracks, due to the fast-eroding of Pluronic F127 from
the composite hydrogel.
Conclusion
A series of novel biodegradable and thermosensitive com-
posite hydrogel were successfully prepared in this work.
The obtained composite hydrogel underwent sol-gel-sol
transition with increase in temperature, which was flow-
ing sol at ambient temperature and became non-flowing
gel at body temperature. By varying the composition of
PECE and Pluronic F127 copolymers, sol-gel-sol transi-
tion behavior and in vitro drug release profile of compos-
ite hydrogel could be adjusted, which was very useful for
its potential applications as in situ gel-forming controlled
drug delivery system.
In vitro release behavior of HK from composite hydrogelFigure 6
In vitro release behavior of HK from composite hydrogel. A: release behavior of S1, S3, an S6 hydrogel with the same 
hydrogel concentration (30 wt%) and initial drug loading amount (1 mg). B: release behavior of 30 wt% S4 hydrogel with differ-
ent initial drug loading amount (1 mg and 2 mg). C: release behavior of 1 mg HK loaded S4 hydrogel with different hydrogel 
concentration (20 wt% and 30 wt%). Error bars represent the standard deviation (n = 3).Page 10 of 13
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In vitro release behavior of BSA from composite hydrogelFigure 7
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